Psychiatric Disorders and Quality of Life in Egyptian Patients with Chronic Immune Thrombocytopenic Purpura: A Single Center Study

  • Sohier Yahia
  • Yahya WahbaEmail author
  • Abdel-Hady El-Gilany
  • Suzy Abdelmabood
  • Mohamed Adel El-Hadidy
  • Ahmad Darwish
  • Ahmed K. Mansour
Original Article


The impact of chronic immune thrombocytopenic purpura (ITP) on the psychological health and quality of life is evident among children and adolescents. We aimed to describe psychological disorders and assess quality of life in children with chronic ITP and compared their results with their healthy peers. A cross-sectional comparative study was carried out in a tertiary care university-affiliated hospital during a period from November, 2015 till April, 2018. We enrolled 119 children with chronic ITP and compared with 220 healthy peers. Relevant demographic and clinical data were collected and statistically analyzed. Quality of life for both patients and control groups was measured using pediatric quality of life inventory version 4 (Arabic one). Also psychiatric evaluation of both groups was done using Arabic version of Mini-International Neuropsychiatric Interview for Children (Mini-KID). Majority of patients (90.7%) exhibited mucocutaneous bleeding. Most of patients (61.3%) did not need any definitive treatment for chronic ITP while 38.6% received second line therapy. About one-third of the patients needed rescue medications to control active bleeding. The scores of all sub-scales of Peds QL 4.0 were significantly decreased among patients group when compared to their healthy peers (P < 0.001). General anxiety disorder and oppositional defiant disorders were the commonest psychiatric disorders among children with chronic ITP. Quality of life in children with chronic ITP is markedly impaired with occurrence of a variable spectrum of psychiatric disorders among the studied patients.


Children Psychiatry Quality of life Immune thrombocytopenic purpura 



Immune thrombocytopenic purpura


Quality of life


Health-related quality of life


Intelligence quotient


Pediatric quality of life inventory version 4



We greatly acknowledge the patients and their families for their patience and help.

Authors’ Contributions

Sohier Yahia: Idea of the research, revising the article draft and final approval of the version to be submitted. Yahya Wahba: Conception and design of the study, collection of clinical data, drafting the article and final approval of the version to be submitted. Abdel-Hady El-Gilany: Analysis and interpretation of data, revising the article draft and final approval of the version to be submitted. Suzy Abdelmabood: Acquisition of hematological data, drafting the article and final approval of the version to be submitted. Mohamed Adel El-Hadidy: Acquisition and analysis of the psychiatric data, revising the article draft and final approval of the version to be submitted. Ahmad Darwish: Analysis of the hematological data, revising the article draft and final approval of the version to be submitted. Ahmed Mansour K: Analysis of the hematological data, conception of the study, drafting the article and final approval of the version to be submitted.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with Ethical Standards

Conflict of interest

Authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Buchanan GR (2005) Thrombocytopenia during. Pediatr Rev 26:401CrossRefGoogle Scholar
  2. 2.
    Provan D, Newland AC (2015) Current management of primary immune thrombocytopenia. Adv Ther 32:875–887CrossRefGoogle Scholar
  3. 3.
    Zufferey A, Kapur R, Semple JW (2017) Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med 6:16CrossRefGoogle Scholar
  4. 4.
    Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. N Engl J Med 346:995–1008CrossRefGoogle Scholar
  5. 5.
    George JN (2006) Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 4:1664–1672CrossRefGoogle Scholar
  6. 6.
    Yong M, Schoonen WM, Li L et al (2010) Epidemiology of paediatric immune thrombocytopenia in the general practice research database. Br J Haematol 149:855–864CrossRefGoogle Scholar
  7. 7.
    Terrell DR, Beebe LA, Vesely SK et al (2010) The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 85:174–180CrossRefGoogle Scholar
  8. 8.
    Neunert CE, Buchanan GR, Blanchette V et al (2009) Relationships among bleeding severity, health-related quality of life, and platelet count in children with immune thrombocytopenic purpura. Pediatr Blood Cancer 53:652–654CrossRefGoogle Scholar
  9. 9.
    Alesci SR, Schwan V, Miesbach W et al (2013) Rare bleeding disorders are associated with depression and anxiety. Hamostaseologie 33:S64–S68PubMedGoogle Scholar
  10. 10.
    Post M (2014) Definitions of quality of life: what has happened and how to move on. Top Spinal Cord Inj Rehabil 20:167–180CrossRefGoogle Scholar
  11. 11.
    Group W, others (1998) The World Health Organization quality of life assessment (WHOQOL): development and general psychometric properties. Soc Sci Med 46:1569–1585CrossRefGoogle Scholar
  12. 12.
    Mokhtar GM, Farid SM, Shaker NM, Farrag KE (2014) Health-related quality of life of Egyptian children with immune thrombocytopenia and their parents. J Pediatr Hematol Oncol 36:194–199CrossRefGoogle Scholar
  13. 13.
    Heitink-Pollé KMJ, Haverman L, Annink KV et al (2014) Health-related quality of life in children with newly diagnosed immune thrombocytopenia. Haematologica 99:1525–1531CrossRefGoogle Scholar
  14. 14.
    Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393CrossRefGoogle Scholar
  15. 15.
    Varni JW, Seid M, Rode CA (1999) The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 37:126–139CrossRefGoogle Scholar
  16. 16.
    Sheehan DV, Lecrubier Y, Sheehan KH et al (1997) The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 12:232–241CrossRefGoogle Scholar
  17. 17.
    Ibrahim M, Bishry Z, Hamed A (2002) Comparison of mini international neuropsychiatric interview for children (MINI-KID) with the schedules for affective disorders and schizophrenia for school aged children, present and lifetime version (KSADS-PL). In: Egyptian sample presenting with childhoo. MD thesis, Ain Shams UniversityGoogle Scholar
  18. 18.
    Neunert C, Lim W, Crowther M et al (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117:4190–4207CrossRefGoogle Scholar
  19. 19.
    Alam MM (2014) Idiopathic thrombocytopenic purpura in children: a 10 years experience at tertiary care hospital. J Pak Med Assoc 64:1358–1362PubMedGoogle Scholar
  20. 20.
    Nazari SH, Abdollah Gorji F, Sadeghi-Koupai MT (2012) Epidemiology of idiopathic thrombocytopenic purpura in children. Iran J Pediatr Hematol Oncol 2:35–39Google Scholar
  21. 21.
    Journeycake JM (2012) Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics. ASH Educ Progr B 2012:444–449Google Scholar
  22. 22.
    Neunert CE, Buchanan GR, Imbach P et al (2008) Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 112:4003–4008CrossRefGoogle Scholar
  23. 23.
    Zhang H, Wang L, Quan M et al (2016) Health-related quality of life in children with chronic immune thrombocytopenia in China. Health Qual Life Outcomes 14:45CrossRefGoogle Scholar
  24. 24.
    Mathias SD, Gao SK, Miller KL et al (2008) Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes 6:13CrossRefGoogle Scholar
  25. 25.
    Stuart FA, Segal TY, Keady S (2005) Adverse psychological effects of corticosteroids in children and adolescents. Arch Dis Child 90:500–506CrossRefGoogle Scholar
  26. 26.
    McMillan R, Bussel JB, George JN et al (2008) Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 83:150–154CrossRefGoogle Scholar
  27. 27.
    Berger M, Gray JA, Roth BL (2009) The expanded biology of serotonin. Annu Rev Med 60:355–366CrossRefGoogle Scholar
  28. 28.
    Rosthøj S, Rajantie J, Treutiger I et al (2012) Duration and morbidity of chronic immune thrombocytopenic purpura in children: five-year follow-up of a nordic cohort. Acta Paediatr 101:761–766CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  1. 1.Pediatrics Department, Faculty of MedicineMansoura UniversityMansouraEgypt
  2. 2.Public Health Department, Faculty of MedicineMansoura UniversityMansouraEgypt
  3. 3.Psychiatric Department, Faculty of MedicineMansoura UniversityMansouraEgypt

Personalised recommendations